Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

From pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example.

Diabetes technology & therapeutics - 1 Jan 2002

Moskowitz David W

Abstract excerpt

Here we report the utility of a molecular epidemiologic approach for common, polygenic diseases. Since 1992, the angiotensin I-converting enzyme (ACE) deletion/deletion (D/D) genotype has been linked to several cardiovascular diseases, including diabetic nephropathy. Earlier, the ACE D/D genotype had been associated with excess tissue ACE activity. We have observed an association of the ACE D/D genotype with a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme Inhibitors
Share to Diabetic Nephropathies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kidney Failure, Chronic

Share to Missouri

Share to Peptidyl-Dipeptidase A

Share to Polycystic Kidney, Autosomal Dominant

Share to Pulmonary Disease, Chronic Obstructive

Share to Sex Characteristics

Source

Identifiers

PMID: 12396747
DOI: 10.1089/152091502760306616

Genes

ACE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

From pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example.PMID 12396747Read ↗

Is angiotensin I-converting enzyme a "master" disease gene?Semantic proximity Read ↗

Advancing management of hypertension through pharmacogenomicsSemantic proximity Read ↗

ACE phenotyping as a first step toward personalized medicine for ACE inhibitors. Why does ACE genotyping not predict the therapeutic efficacy of ACE inhibition?Semantic proximity Read ↗

Pharmacogenomics of hypertension in chronic kidney disease: the CKD-PGX studySemantic proximity Read ↗

ACE inhibition and cardiometabolic risk factors, lung <i>ACE2</i> and <i>TMPRSS2</i> gene expression, and plasma ACE2 levels: a Mendelian randomization studySemantic proximity Read ↗

Will angiotensin converting enzyme genotype, receptor mutation identification, and other miracles of molecular biology permit reduction of NNT?Semantic proximity Read ↗

Genes, Environment, Intermediate Phenotypes, and the Pathogenesis of Diabetic Nephropathy.Semantic proximity Read ↗

[Tailor-made medicine and genetic polymorphism: Pneumonia and hypertension].Semantic proximity Read ↗

Preventing and controlling hypertension in the era of genomic innovation and environmental transformation.Semantic proximity Read ↗

ACE insertion deletion polymorphisms and effectiveness of statin therapy.Semantic proximity Read ↗

Angiotensin converting enzyme gene I/D polymorphism in essential hypertension and nephroangiosclerosis.Semantic proximity Read ↗

Phenotyping Angiotensin-Converting Enzyme in Blood: A Necessary Approach for Precision Medicine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.